Abstract. T helper 17 (Th17), T cytotoxic 17 (Tc17) and regulatory T (Treg) cells serve important roles in a number of inflammatory and autoimmune diseases. The aim of the present study was to examine the distribution of Th17, Tc17 and Treg cells in patients with differentiated thyroid cancer (DTC) prior to as well as 7, 30 and 90 days following radioactive iodine-131 ( 131 I) therapy, and to elucidate the probable effects of 131 I therapy on Th17/Tc17 and Treg/Th17 cells in patients with DTC. A total of 40 patients with DTC (26 female; 14 male) between the ages of 24 and 72 years, as well as 13 age-and sex-matched healthy subjects were included in this study. The number of Th17, Tc17 and Treg cells in the peripheral blood of patients with DTC and of healthy Controls were assessed by flow cytometry. Th17 and Tc17 cells were counted as percentages of the number of CD3 + T cells; Treg cells were counted as a percentage of the number of CD4 +
Introduction
The incidence rate of thyroid tumor has increased over the past 30 years and tends to affect the young (1) (2) (3) . Although thyroid carcinoma is rare and accounts for approximately 1% among human malignancies, it is the most common malignancy of the endocrine system (4, 5) . Among thyroid malignancies, differentiated thyroid cancer (DTC) comprises the vast majority, ~90%, and includes papillary and follicular histological types (6) . DTC cells have the ability to concentrate iodine and to synthesize and release thyroid hormones. This characteristic enables the administration of radioactive iodine-131 ( 131 I) to treat metastatic diseases and to ablate remnant thyroid tissues following thyroidectomy (7) . In accordance with the European Association of Nuclear Medicine guidelines, certain patients with DTC are required to receive 131 I therapy after surgery (8) .
Immunological mechanisms are vital in the surveillance of malignancy and the control of cancer progression. Immune responses against DTC have long been recognized. T cells are crucial participants in the immune response. Previous studies have revealed that the imbalance between T helper (Th)1 and Th2 cells is a major immunological mechanism in the pathogenesis of DTC (9) (10) (11) (16, 17) . Treg cells secrete TGF-β and IL-10. The release of IL-10 aids Treg cells to greatly repress host immune responses, mainly by contributing to impaired antitumorimmunity in cancer-bearing subjects (18) . In previous reports, the reciprocal relationships between Th17 and either Tc17 or Treg cell numbers in tumors have been emphasized. The imbalance between Th17 and Tc17 or Treg cells has been observed in several types of tumor, such as gastric (19) , ovarian (20) and prostate cancer (21) . In particular, recent studies have revealed that Thl7, Tc17 and Treg cell levels are also abnormal in patients with DTC (11, 15, 19, 22) ; however, the specific relationships between Th17 cells and Tc17 or Treg cells, as well as the related cytokine secretion, remain unclear.
131
I treatment may have an effect on the hematopoietic system of patients with DTC, particularly on the lymphocytes; however, there little is known about T cells in patients with DTC patients following 131 I treatment. Therefore, the present study aimed to investigate the effects of 131 I on the immune cell subsets, Th17, Tc17 and Treg cells, and the related cytokine production in patients with DTC.
Materials and methods
Patients. The study population included 40 patients with DTC (26 female; 14 male; age, 24-72 years); patient characteristics are provided in Table I . Among them, 29 (72.5%) had papillary carcinomas and 11 (27.5%) had follicular carcinomas. None of the patients had autoimmune diseases, chronic inflammation, allergic disease or other conditions that may affect the tested parameters. All patients with DTC underwent total thyroidectomy. At 4-6 weeks following surgery, patients received a low-iodine diet (<50 µg/day) for 1-2 weeks and subsequently were treated with a single dose of 3.7 GBq (100 mCi) of 131 I (Chengdu Gaotong Isotope Cooperation, Chengdu, China) administered orally according to the EANM guidelines (8, 12) . The Control group comprised 13 age-and sex-matched healthy subjects. This study protocol was approved by the Ethics Committee of The First Affiliated Hospital of Zhejiang Chinese Medical University (Hangzhou, China). All patients and Control subjects provided informed written consent prior to enrollment in the study.
Peripheral blood mononuclear cells (PBMCs) and serum preparation. Peripheral blood samples (5 ml) from the study subjects were collected in EDTA tubes following venipuncture. Blood (5 ml) was collected from Control subjects only once, whereas samples were collected from patients with DTC at day 0, as well as 7, 30 and 90 days following 131 I treatment. The blood (0.5 ml per subject) was combined with RPMI-1640 medium (5 ml; Sigma-Aldrich; Merck KGaA, Darmstadt, Germany) containing 10% fetal bovine serum (FBS, Sigma-Aldrich; Merck KGaA), 2 mM glutamine, 100 U/ml penicillin and 100 U/ml streptomycin and incubated at 37˚C for 72 h. The supernatant was harvested by centrifugation at 1,400 x g for 12 min at room temperature and stored at -20˚C until required (11) . Serum for the detection of cytokine levels was obtained by centrifugation at 2,000 x g for 15 min at 4˚C and stored at -80˚C. The intracellular cytokine levels were assessed by flow cytometry to identify the cytokine-producing cells, as previously described (13) . Briefly, PBMCs ( 2x10 7 ) were stimulated with phorbol myristate acetate (25 ng/ml), monensin (1.7 µg/ml) and ionomycin (1 µg/ml; all were purchased from Alexis Biochemicals; Enzo Life Sciences, Inc., Farmingdale, NY, USA). The cells were incubated with anti-CD3-phycoerythrin (PE)-Cy5 (0.6 µg/ml, 15-0038-42, eBioscience; Thermo Fisher Scientific, Inc., Waltham,, MA, USA) and anti-CD8-fluoresciene isothiocyanate (FITC) (5 µg/ml, MHCD0801, eBioscience; Thermo Fisher Scientific, Inc.) monoclonal antibodies at room temperature in the dark for 15 min. Following fixation with 4% paraformaldehyde (Sigma-Aldrich; Merck KGaA) and permeabilization with 1% saponin (Sigma-Aldrich; Merck KGaA) for 15 min at room temperature, cells were stained anti-IL17-PE monoclonal antibody (2.5 µg/ml, 12-7517-42, eBioscience; Thermo Fisher Scientific, Inc.) at room temperature in the dark for 15 min. Similarly, the culture supernatant was incubated with a mixture of anti-CD4-FITC monoclonal antibody (2.5 µg/ml, 11-0048-42, eBioscience; Thermo Fisher Scientific, Inc.) and anti-CD25-allophycocyanin (APC) monoclonal antibody (0.6 µg/ml, 17-0257-42, eBioscience; Thermo Fisher Scientific, Inc.) at 4˚C in the dark for 30 min. Following fixation and permeabilization, the cells were stained with anti-Foxp3-PE monoclonal antibody (2.5 µg/ml, 12-4776-42 eBioscience; Thermo Fisher Scientific, Inc.) at 4˚C in the dark for 45 min. Flow cytometric analysis was performed using a FACSCalibur (BD Biosciences, Franklin Lakes, NJ, USA). Data were analyzed with the BD FACSDiva software (version 6.0, BD Biosciences) (13) .
Flow cytometric analysis of
ELISA. Serum was used to determine cytokine levels, including IL-10 (F01360), IL-17 (F01450), IL-23 (F01534) and TGF-β (F02750), with a quantitative sandwich-enzyme immunoassay technique, according to the manufacturer's instructions (Westang; Biotech Co., Ltd., Shanghai, China). All samples were measured in duplicate. Statistical analysis. Data are expressed as the mean ± standard deviation and median values. Differences between groups were determined using one-way analysis of the variance, followed by the Tukey's test. Correlation analysis was evaluated by Pearson's correlation test. All tests were performed using SPSS 13.0 (SPSS, Inc., Chicago, IL, USA). P<0.05 was considered to indicate a statistically significant difference.
Results

Frequencies of Th17 and Tc17 cells in DTC patients preand post-
131
I therapy. The frequency of Th17 and Tc17 cells in the peripheral blood samples from 13 Control subjects and 40 patients with DTC who had total thyroidectomy were analyzed by flow cytometry prior to and following 131 I therapy. The percentage of Th17 and Tc17 cells was significantly increased in patients with DTC at day 0 compared with those in the Control group (Fig. 1A-C) . At days 7, 30 and 90 following 131 I therapy, the percentage of Th17 and Tc17 cells significantly decreased compared with the levels at day 0; in addition, at 90 days following 131 I therapy, no significant difference in the percentage of Th17 and Tc17 cells was detected between patients with DTC and healthy subjects (Fig. 1A-C) . (Fig. 1D and E) . At 7, 30 and 90 days following therapy, the percentage of Treg cells was significantly decreased compared with treated patients at day 0; at 90 days post-therapy, no significant difference in the percentage of Treg cells was indicated between patients with DTC and healthy Control subjects ( Fig. 1D and E) .
Serum concentrations of IL-17, IL-23, IL-10 and TGF-β1 in patients with DTC pre-and post-
131 I therapy. Serum levels of IL-17, IL-23, IL-10 and TGF-β1 were measured by ELISA. IL-17 and IL-23 levels were significantly increased in patients with DTC at day 0 compared with the levels in the healthy Control patients ( Fig. 2A and B) , which was consistent with the elevated prevalence of Th17 and Tc17 cells in these patients. Subsequently, at 7, 30 and 90 days following 131 I therapy, IL-17 and IL-23 levels were significantly decreased; no significant difference was indicated for the expression levels of IL-17 and IL-23 in patients with DTC 90 days post-therapy compared with healthy subjects ( Fig. 2A and B) . Similarly, the serum levels of IL-10 and TGF-β1 were significantly increased in patients with DTC at day 0 compared with the Control patients ( Fig. 2C and D) , which was consistent with the elevated prevalence of Treg cells in these patients. At days 7, 30 and 90 post-therapy, IL-10 and TGF-β1 levels were significantly decreased, and no significant difference was indicated for the levels of IL-10 and TGF-β1 in patients with DTC at 90 days compared with healthy patients (Fig. 2C and D) . 
Balances between Th17/Tc17 and Treg/Th17 cells pre-and post-
131
I therapy. Compared with the Controls, the Th17/Tc17 ratio was significantly elevated in patients with DTC at day 0 (Fig. 3A) . Furthermore, this ratio in patients with DTC was reduced following 131 I therapy for 7 days. Subsequently, this ratio was unexpectedly increased after 131 I therapy for 30 days. Additionally, the Th17/Tc17 ratio was not significantly different from the Control group at 90 days following 131 I therapy (Fig. 3A) . It is possible that 131 I also resulted in radioactive damage to DTC patients. Conversely, the Treg/Th17 ratio was significantly decreased in patients with DTC compared with the Controls, and this ratio in patients with DTC was elevated following 131 I therapy for 7 days. Subsequently, at 30 days post-therapy, this ratio was decreased. Furthermore, no significant difference was indicated in the Treg/Th17 ratio between patients with DTC and the healthy Controls following 131 I therapy for 90 days (Fig. 3B) . In addition, a strong positive correlation between Th17 and Tc17 cell levels was observed in the healthy Controls and in the DTC patients that received 131 I treatment for 90 days (Fig. 4A) ; while a weak positive correlation between Th17 and Treg cell levels was identified in the healthy Controls and no obvious correlation between Th17 and Treg cells was observed in patients with DTC pre-and post-131 I therapy during the entire treatment period (Fig. 4B) . immune cells that are important in antitumor immunity and inflammation (19, 22, 24) . Additionally, it was reported that higher levels of Treg cells are associated with poor survival (25) . These findings suggested the probable involvement of these three cells in the development of DTC. In the present study, a significant increase in the levels of Th17, Tc17 and Treg cells was observed in patients with DTC; these results were similar to those observed in endometrial carcinoma (13) , which suggested that these three effector T cells may serve important roles in the progression of DTC.
Th17 and Tc17 cells have obtained an increasing amount of attention owing to their roles in tumorigenesis; their levels, as well as IL-17 production, are upregulated in the peripheral blood of patients with cancer (19, 26, 27) . Similarly, results from the present study revealed significant increases in the number of Th17 and Tc17 cells in the peripheral blood of patients with DTC. In addition, a strong positive correlation was identified between Th17 and Tc17 cells, and the Th17/Tc17 ratio was significantly elevated in patients with DTC, which suggests that the increase in Th17 cells may exceed that of Tc17 cells. In addition, an elevated proportion of Treg cells, and an imbalance between Treg and Th17 cells in patients with DTC were also observed. Treg cells are known to inhibit host immunity (28) ; it was reported that higher levels of Treg cells is associated with poor survival (25) . Increased Treg frequency may result in tolerance of tumor cells from the host and may aid DTC cell survival and migration. In the present study, the Treg/Th17 ratio was significantly decreased in patients with DTC, and the positive correlation between Th17 and Treg cells observed in healthy Controls disappeared in patients with DTC. Similar results have been demonstrated in patients with cervical cancer and prostate cancer (21, 26) . The present study hypothesized that Th17 and Treg cell levels increased owing to immune reactions in the tumor microenvironment. Results suggested that the number of Th17 cells produced was greater compared with the number of Treg cells. Although cytokine concentrations have been previously analyzed in patients with different cancers (29) (30) (31) , they have seldom been examined in patients with DTCs. Results from the present study also demonstrated that levels of cytokines IL-17, IL-23, IL-10 and TGF-β1 levels were significantly elevated in patients with DTC.
However, alterations of Th17, Tc17, Treg cell levels and related cytokine secretion in patients with DTC that were treated with 131 I are not distinct. It has been reported previously that iodine-125 stimulates the antitumor immune response by facilitating Th2/Th1 deviation in patients with hepatocellular carcinoma (32) . In addition, the proportions of Treg, IL-10 and TGF-β levels were significantly reduced in patients with Graves disease, some of which recovered following 131 I treatment (33) . It has also been reported that Th2 cytokine levels, including IL-4, IL-6 and IL-10, were reduced in patients with DTC following 131 I therapy (11) . Another previous study reported that the IL-23/Th17 axis may serve a key role in the pathogenesis of Graves disease, and the levels of serum IL-17 and IL-23 were demonstrated to gradually decrease following treatment with 131 I (34) . Results from the present study indicated a significant decrease in the number of Th17, Tc17, Treg cells as well as in the production of related cytokines, including IL-17, IL-23, IL-10 and TGF-β1, in patients with DTC following 131 I therapy; these results differed from those reported by Jing et al (33) , perhaps owing to the differences in the number and type of inflammatory cells associated with DTC and Graves disease. In addition, the ratio of Th17/Tc17 was significantly elevated in patients with DTC at day 0 and this ratio fluctuated significantly following 
